Role of chemokines and their receptors in cancer

Current Pharmaceutical Design

Volumn 15, Issue 29, 2009, Pages 3396-3416

  Kruizinga, Roeliene C ^a   Bestebroer, Jovanka ^b   Berghuis, Paul ^a   De Haas, Carla J C ^b   Links, Thera P ^a   De Vries, Elisabeth G E ^a   Walenkamp, Annemiek M E ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cancer; Chemokine; Chemokine receptor; Mechanism of action; Metastasis; Migration

Indexed keywords

AMG 487; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FORMYLPEPTIDE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 2; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BRAIN DEVELOPMENT; CANCER GRADING; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; EMBRYO DEVELOPMENT; GENE ACTIVATION; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; HEMATOPOIESIS; HUMAN; IMMUNITY; KIDNEY CARCINOMA; LEUKOCYTE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MENSTRUAL CYCLE; METASTASIS; NIDATION; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TREATMENT INDICATION; UPREGULATION;

ANIMALS; CHEMOKINES; FEMALE; HUMANS; NEOPLASMS; PREGNANCY; RECEPTORS, CHEMOKINE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 70449434574     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789105081     Document Type: Review

References (233)

1. Zlotnik A. Chemokines and cancer. Int J Cancer 2006; 119: 2026-2029.
2. Takeuchi H, Kitago M, Hoon DS. Effects of chemokines on tumor metastasis. Cancer Treat Res 2007; 135: 177-184.
3. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-8612. (Pubitemid 39552073)
4. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-1837. (Pubitemid 34408510)
5. Palczewski K. G protein-coupled receptor rhodopsin. Annu Rev Biochem 2006; 75: 743-767.
6. Sabirsh A, Bywater RP, Bristulf J, Owman C, Haeggstrom JZ. Residues from transmembrane helices 3 and 5 participate in leuko-triene B4 binding to BLT1. Biochemistry 2006; 45: 5733-5744.
7. Mills JS, Miettinen HM, Cummings D, Jesaitis AJ. Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met- Trp-Leu-Leu. J Biol Chem 2000; 275: 39012-39017. (Pubitemid 32058913)
8. Ishii I, Izumi T, Tsukamoto H, Umeyama H, Ui M, Shimizu T. Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants. J Biol Chem 1997; 272: 7846-7854. (Pubitemid 27137343)
9. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007; 25: 787-820.
10. Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, Van RG, et al. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 1994; 91: 1214-1218. (Pubitemid 24058980)
11. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 2002; 42: 469-499.
12. Hamm HE. The many faces of G protein signaling. J Biol Chem 1998; 273: 669-672.
13. Dominguez F, Pellicer A, Simon C. Paracrine dialogue in implantation. Mol Cell Endocrinol 2002; 186: 175-181.
14. Ozenci CC, Korgun ET, Demir R. Immunohistochemical detection of CD45+, CD56+, and CD14+ cells in human decidua during early pregnancy. Early Pregnancy 2001; 5: 164-175.
15. Moffett-King A, Entrican G, Ellis S, Hutchinson J, Bainbridge D. Natural killer cells and reproduction. Trends Immunol 2002; 23: 332-333.
16. Trundley A, Moffett A. Human uterine leukocytes and pregnancy. Tissue Antigens 2004; 63: 1-12.
17. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002; 2: 656-663.
18. Croy BA, Esadeg S, Chantakru S, van den HM, Paffaro VA, He H, et al. Update on pathways regulating the activation of uterine Natural Killer cells, their interactions with decidual spiral arteries and homing of their precursors to the uterus. J Reprod Immunol 2003; 59: 175-191. (Pubitemid 36957854)
19. Jones RL, Hannan NJ, Kaitu'u TJ, Zhang J, Salamonsen LA. Identification of chemokines important for leukocyte recruitment to the human endometrium at the times of embryo implantation and menstruation. J Clin Endocrinol Metab 2004; 89: 6155-6167.
20. Robertson MJ, Williams BT, Christopherson K, Brahmi Z, Hromas R. Regulation of human natural killer cell migration and proliferation by the exodus subfamily of CC chemokines. Cell Immunol 2000; 199: 8-14. (Pubitemid 30118590)
21. Kitaya K, Nakayama T, Okubo T, Kuroboshi H, Fushiki S, Honjo H. Expression of macrophage inflammatory protein-1beta in human endometrium: its role in endometrial recruitment of natural killer cells. J Clin Endocrinol Metab 2003; 88: 1809-1814. (Pubitemid 36623409)
22. Drake PM, Red-Horse K, Fisher SJ. Reciprocal chemokine receptor and ligand expression in the human placenta: implications for cytotrophoblast differentiation. Dev Dyn 2004; 229: 877-885. (Pubitemid 38429116)
23. Red-Horse K, Drake PM, Gunn MD, Fisher SJ. Chemokine ligand and receptor expression in the pregnant uterus: reciprocal patterns in complementary cell subsets suggest functional roles. Am J Pathol 2001; 159: 2199-2213. (Pubitemid 33104274)
24. Dominguez F, Pellicer A, Simon C. The chemokine connection: hormonal and embryonic regulation at the human maternal-embryonic interface--a review. Placenta 2003; 24 (Suppl B): S48-S55. (Pubitemid 37321794)
25. Drake PM, Gunn MD, Charo IF, Tsou CL, Zhou Y, Huang L, et al. Human placental cytotrophoblasts attract monocytes and CD56(bright) natural killer cells via the actions of monocyte inflammatory protein 1alpha. J Exp Med 2001; 193: 1199-1212. (Pubitemid 32488372)
26. Dominguez F, Galan A, Martin JJ, Remohi J, Pellicer A, Simon C. Hormonal and embryonic regulation of chemokine receptors CXCR1, CXCR4, CCR5 and CCR2B in the human endometrium and the human blastocyst. Mol Hum Reprod 2003; 9: 189-198. (Pubitemid 36511292)
27. Sato Y, Higuchi T, Yoshioka S, Tatsumi K, Fujiwara H, Fujii S. Trophoblasts acquire a chemokine receptor, CCR1, as they differentiate towards invasive phenotype. Development (Cambridge, England) 2003; 130: 5519-5532. (Pubitemid 37484018)
28. Salamonsen LA, Hannan NJ, Dimitriadis E. Cytokines and chemokines during human embryo implantation: roles in implantation and early placentation. Semin Reprod Med 2007; 25: 437-444. (Pubitemid 350058430)
29. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006; 20: 1915-1924. (Pubitemid 44614878)
30. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-638. (Pubitemid 26268957)
31. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595-599. (Pubitemid 28319251)
32. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694. (Pubitemid 34752479)
33. Broxmeyer HE, Cooper S, Kohli L, Hangoc G, Lee Y, Mantel C, et al. Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/ antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol 2003; 170: 421-429. (Pubitemid 36026167)
34. Broxmeyer HE, Kohli L, Kim CH, Lee Y, Mantel C, Cooper S, et al. Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol 2003; 73: 630-638. (Pubitemid 38040476)
35. Broxmeyer HE, Sherry B, Cooper S, Lu L, Maze R, Beckmann MP, et al. Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol 1993; 150: 3448-3458. (Pubitemid 23129725)
36. McGrath KE, Koniski AD, Maltby KM, McGann JK, Palis J. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol 1999; 213: 442-456. (Pubitemid 29444352)
37. Bagri A, Gurney T, He X, Zou YR, Littman DR, Tessier-Lavigne M, et al. The chemokine SDF1 regulates migration of dentate granule cells. Development (Cambridge, England) 2002; 129: 4249-4260.
38. Lu M, Grove EA, Miller RJ. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc Natl Acad Sci USA 2002; 99: 7090-7095. (Pubitemid 34526260)
39. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1- deficient mice. Proc Natl Acad Sci USA 1998; 95: 9448-9453. (Pubitemid 28506251)
40. Reiss K, Mentlein R, Sievers J, Hartmann D. Stromal cell-derived factor 1 is secreted by meningeal cells and acts as chemotactic factor on neuronal stem cells of the cerebellar external granular layer. Neuroscience 2002; 115: 295-305. (Pubitemid 35232708)
41. Borrell V, Marin O. Meninges control tangential migration of hem-derived Cajal-Retzius cells via CXCL12/CXCR4 signaling. Nat Neurosci 2006; 9: 1284-1293. (Pubitemid 44454270)
42. Stumm RK, Zhou C, Ara T, Lazarini F, Dubois-Dalcq M, Nagasawa T, et al. CXCR4 regulates interneuron migration in the developing neocortex. J Neurosci 2003; 23: 5123-5130. (Pubitemid 36793240)
43. Super H, Del Rio JA, Martinez A, Perez-Sust P, Soriano E. Disruption of neuronal migration and radial glia in the developing cerebral cortex following ablation of Cajal-Retzius cells. Cereb Cortex 2000; 10: 602-613. (Pubitemid 30387839)
44. D'Arcangelo G, Miao GG, Chen SC, Soares HD, Morgan JI, Curran T. A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature 1995; 374: 719-723.
45. Letinic K, Zoncu R, Rakic P. Origin of GABAergic neurons in the human neocortex. Nature 2002; 417: 645-649. (Pubitemid 34614822)
46. Uylings HB. Development of the cerebral cortex in rodents and man. Eur J Morphol 2000; 38: 309-312. (Pubitemid 32009773)
47. de Carlos JA, Lopez-Mascaraque L, Valverde F. Dynamics of cell migration from the lateral ganglionic eminence in the rat. J Neurosci 1996; 16: 6146-6156. (Pubitemid 26313990)
48. DeDiego I, Smith-Fernandez A, Fairen A. Cortical cells that migrate beyond area boundaries: characterization of an early neuronal population in the lower intermediate zone of prenatal rats. Eur J Neurosci 1994; 6: 983-997. (Pubitemid 24185322)
49. Anderson SA, Kaznowski CE, Horn C, Rubenstein JL, McConnell SK. Distinct origins of neocortical projection neurons and interneurons in vivo. Cereb Cortex 2002; 12: 702-709. (Pubitemid 34680534)
50. Stumm RK, Rummel J, Junker V, Culmsee C, Pfeiffer M, Krieglstein J, et al. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J Neurosci 2002; 22: 5865-5878. (Pubitemid 35387631)
51. Tiveron MC, Rossel M, Moepps B, Zhang YL, Seidenfaden R, Favor J, et al. Molecular interaction between projection neuron precursors and invading interneurons via stromal-derived factor 1 (CXCL12)/CXCR4 signaling in the cortical subventricular zone/ intermediate zone. J Neurosci 2006; 26: 13273-13278. (Pubitemid 46011637)
52. Li G, Adesnik H, Li J, Long J, Nicoll RA, Rubenstein JL, et al. Regional distribution of cortical interneurons and development of inhibitory tone are regulated by Cxcl12/Cxcr4 signaling. J Neurosci 2008; 28: 1085-1098. (Pubitemid 351186344)
53. Sotelo C. Cellular and genetic regulation of the development of the cerebellar system. Prog Neurobiol 2004; 72: 295-339. (Pubitemid 38626160)
54. Bentley D, O'Connor TP. Cytoskeletal events in growth cone steering. Curr Opin Neurobiol 1994; 4: 43-48. (Pubitemid 24059354)
55. Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. Science 1996; 274: 1123-1133.
56. Song H, Poo M. The cell biology of neuronal navigation. Nat Cell Biol 2001; 3: E81-E88.
57. Xiang Y, Li Y, Zhang Z, Cui K, Wang S, Yuan XB, et al. Nerve growth cone guidance mediated by G protein-coupled receptors. Nat Neurosci 2002; 5: 843-848. (Pubitemid 34976648)
58. Arakawa Y, Bito H, Furuyashiki T, Tsuji T, Takemoto-Kimura S, Kimura K, et al. Control of axon elongation via an SDF-1alpha/ Rho/mDia pathway in cultured cerebellar granule neurons. J Cell Biol 2003; 161: 381-391. (Pubitemid 36529855)
59. Pujol F, Kitabgi P, Boudin H. The chemokine SDF-1 differentially regulates axonal elongation and branching in hippocampal neurons. J Cell Sci 2005; 118: 1071-1080. (Pubitemid 40484895)
60. Lieberam I, Agalliu D, Nagasawa T, Ericson J, Jessell TM. A Cxcl12-CXCR4 chemokine signaling pathway defines the initial trajectory of mammalian motor axons. Neuron 2005; 47: 667-679. (Pubitemid 41208006)
61. Tran PB, Miller RJ. Chemokine receptors in the brain: a developing story. J Comp Neurol 2003; 457: 1-6. (Pubitemid 36172568)
62. Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang Y, Qin S, et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 1998; 273: 23169-23175. (Pubitemid 28417500)
63. Edman LC, Mira H, Erices A, Malmersjo S, Andersson E, Uhlen P, et al. Alpha-chemokines regulate proliferation, neurogenesis, and dopaminergic differentiation of ventral midbrain precursors and neurospheres. Stem Cells 2008; 26: 1891-1900.
64. Tsai HH, Frost E, To V, Robinson S, Ffrench-Constant C, Geertman R, et al. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002; 110: 373-383. (Pubitemid 34899385)
65. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393: 591-594. (Pubitemid 28319250)
66. Panzer U, Steinmetz OM, Stahl RA, Wolf G. Kidney diseases and chemokines. Curr Drug Targets 2006; 7: 65-80.
67. Grone HJ, Cohen CD, Grone E, Schmidt C, Kretzler M, Schlondorff D, et al. Spatial and temporally restricted expression of chemokines and chemokine receptors in the developing human kidney. J Am Soc Nephrol 2002; 13: 957-967. (Pubitemid 34274092)
68. de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, Heezius EC, et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 2004; 199: 687-695. (Pubitemid 38316435)
69. Rooijakkers SH, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 2005; 6: 920-927. (Pubitemid 43090447)
70. Jongerius I, Kohl J, Pandey MK, Ruyken M, Van Kessel KP, van Strijp JA, et al. Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med 2007; 204: 2461-2471. (Pubitemid 47529330)
71. Prat C, Bestebroer J, de Haas CJ, van Strijp JA, Van Kessel KP. A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J Immunol 2006; 177: 8017-8026. (Pubitemid 44846319)
72. Bestebroer J, Van Kessel KP, Azouagh H, Walenkamp AM, Boer IG, Romijn RA, et al. Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins. Blood 2009; 113: 328-337.
73. Walenkamp AME, Bestebroer J, Boer IGJ, Kruizinga R, Verheul HM, van Strijp JAG, et al. Staphylococcal SSL5 binding to human leukemia cells inhibits cell adhesion to endothelial cells and platelets. Cellular Oncology. 2009.In Press
74. Walenkamp AM, Boer IG, Bestebroer J, Rozeveld D, Timmer-Bosscha H, Hemrika W, et al. Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration. Neoplasia 2009; 11: 333-344.
75. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004; 14: 181-185.
76. Zlotnik A. Chemokines and cancer. Int J Cancer 2006; 119: 2026-2029.
77. Takeuchi H, Kitago M, Hoon DS. Effects of chemokines on tumor metastasis. Cancer Treat Res 2007; 135: 177-184.
78. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-8612. (Pubitemid 39552073)
79. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104: 550-557.
80. Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink FM, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol 2001; 115: 545-553. (Pubitemid 34015643)
81. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56. (Pubitemid 32225831)
82. Zeelenberg IS, Ruuls-Van SL, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003; 63: 3833-3839. (Pubitemid 36793074)
83. Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP. CXCR- 4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol 1998; 69: 99-104. (Pubitemid 28515968)
84. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001; 167: 4747-4757. (Pubitemid 32954357)
85. Tanabe S, Heesen M, Yoshizawa I, Berman MA, Luo Y, Bleul CC, et al. Functional expression of the CXC-chemokine receptor- 4/fusin on mouse microglial cells and astrocytes. J Immunol 1997; 159: 905-911. (Pubitemid 127484244)
86. Rempel SA, Dudas S, Ge S, Gutierrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 2000; 6: 102-111. (Pubitemid 30064982)
87. Ohtani Y, Minami M, Kawaguchi N, Nishiyori A, Yamamoto J, Takami S, et al. Expression of stromal cell-derived factor-1 and CXCR4 chemokine receptor mRNAs in cultured rat glial and neuronal cells. Neurosci Lett 1998; 249: 163-166. (Pubitemid 28331541)
88. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002; 277: 49481-49487. (Pubitemid 36014384)
89. Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003; 63: 1969-1974. (Pubitemid 36460865)
90. Pistoia V, Corcione A, Dallegri F, Ottonello L. Lymphoproliferative disorders and chemokines. Curr Drug Targets 2006; 7: 81-90.
91. Zeelenberg IS, Ruuls-Van SL, Roos E. Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma. J Clin Invest 2001; 108: 269-277. (Pubitemid 32656251)
92. Narducci MG, Scala E, Bresin A, Caprini E, Picchio MC, Remotti D, et al. Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 2006; 107: 1108-1115. (Pubitemid 43156312)
93. Bertolini F, Dell'Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002; 62: 3106-3112. (Pubitemid 34602402)
94. Burger JA, Burkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 2007; 137: 288-296. (Pubitemid 46650259)
95. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201-2213. (Pubitemid 44352240)
96. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005; 280: 35760-35766. (Pubitemid 41532769)
97. Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, et al. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol 2008; 84: 1130-1140.
98. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A 2007; 104: 14759-14764. (Pubitemid 350003216)
99. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201-2213. (Pubitemid 44352240)
100. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005; 106: 1824-1830.
101. Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim J, Suzuki Y, et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 1999; 73: 7489-7496. (Pubitemid 29383232)
102. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999; 73: 1719-1723. (Pubitemid 29036837)
103. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998; 253: 877-882. (Pubitemid 29039238)
104. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37: 1253-1262. (Pubitemid 39281506)
105. Hatse S, Princen K, De CE, Rosenkilde MM, Schwartz TW, Hernandez-Abad PE, et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol 2005; 70: 752-761. (Pubitemid 41058710)
106. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000; 95: 627-632. (Pubitemid 30041679)
107. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol 2009; 217: 21-31.
108. Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006; 66: 7701-7707. (Pubitemid 44289229)
109. Engl T, Relja B, Blumenberg C, Muller I, Ringel EM, Beecken WD, et al. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006; 78: 1784-1793. (Pubitemid 43295576)
110. Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, et al. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 2008; 179: 61-66. (Pubitemid 350216740)
111. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007; 67: 3396-3405. (Pubitemid 46724880)
112. Trentin L, Agostini C, Facco M, Piazza F, Perin A, Siviero M, et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest 1999; 104: 115-121. (Pubitemid 29534351)
113. Kawada K, Sonoshita M, Sakashita H, Takabayashi A, Yamaoka Y, Manabe T, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004; 64: 4010-4017. (Pubitemid 38697317)
114. Suefuji H, Ohshima K, Karube K, Kawano R, Nabeshima K, Suzumiya J, et al. CXCR3-positive B cells found at elevated frequency in the peripheral blood of patients with MALT lymphoma are attracted by MIG and belong to the lymphoma clone. Int J Cancer 2005; 114: 896-901. (Pubitemid 40504469)
115. Pan J, Burdick MD, Belperio JA, Xue YY, Gerard C, Sharma S, et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 2006; 176: 1456-1464. (Pubitemid 43134288)
116. Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, et al. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother 2007; 30: 417-424. (Pubitemid 46684431)
117. Eisman R, Surrey S, Ramachandran B, Schwartz E, Poncz M. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood 1990; 76: 336-344. (Pubitemid 20225524)
118. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP- 10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197: 1537-1549. (Pubitemid 36682550)
119. Gacci M, Serni S, Lapini A, Vittori G, Alessandrini M, Nesi G, et al. CXCR3-B expression correlates with tumor necrosis extension in renal cell carcinoma. J Urol 2009; 181: 843-848.
120. Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, bou-Slaybi A, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008; 111: 1201-1207.
121. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98: 3352-3357. (Pubitemid 32220849)
122. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247: 77-79. (Pubitemid 20059941)
123. Suyama T, Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ichikawa T, et al. Up-regulation of the interferon gamma (IFN-gamma)- inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer 2005; 103: 258-267. (Pubitemid 40129284)
124. Tonn GR, Wong SG, Wong SC, Johnson MG, Ma J, Cho R, et al. An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4- dihydro-pyrido[2,3-d]pyrimidin-2-yl]- ethy l}-N-pyridin-3-ylmethyl- 2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing. Drug Metab Dispos 2009; 37: 502-513.
125. Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 2004; 104: 502-508. (Pubitemid 38900034)
126. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101: 3568-3573. (Pubitemid 36857943)
127. Maggio EM, Van Den BA, Visser L, Diepstra A, Kluiver J, Emmens R, et al. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer 2002; 99: 665-672. (Pubitemid 34538745)
128. Makishima H, Ito T, Asano N, Nakazawa H, Shimodaira S, Kamijo Y, et al. Significance of chemokine receptor expression in aggressive NK cell leukemia. Leukemia 2005; 19: 1169-1174. (Pubitemid 40946000)
129. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999; 59: 4681-4687. (Pubitemid 29428976)
130. Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005; 116: 949-956. (Pubitemid 41209203)
131. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006; 66: 124-134. (Pubitemid 43191234)
132. van Deventer HW, O'Connor W, Jr., Brickey WJ, Aris RM, Ting JP, Serody JS. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res 2005; 65: 3374-3379.
133. Sugasawa H, Ichikura T, Tsujimoto H, Kinoshita M, Morita D, Ono S, et al. Prognostic significance of expression of CCL5/ RANTES receptors in patients with gastric cancer. J Surg Oncol 2008; 97: 445-450.
134. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003; 198: 1381-1389. (Pubitemid 37392483)
135. Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/ Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769-776.
136. Boehlen F, Clemetson KJ. Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice? Transfus Med 2001; 11: 403-417.
137. Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, Oh J, et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998; 102: 1112-1124. (Pubitemid 28436271)
138. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol 1996; 59: 81-89.
139. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002; 62: 1093-1102. (Pubitemid 34160293)
140. Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol 2002; 32: 404-412.
141. Wu Y, Li YY, Matsushima K, Baba T, Mukaida N. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J Immunol 2008; 181: 6384-6393.
142. van Deventer HW, Wu QP, Bergstralh DT, Davis BK, O'Connor BP, Ting JP, et al. C-C chemokine receptor 5 on pulmonary fibrocytes facilitates migration and promotes metastasis via matrix metalloproteinase 9. Am J Pathol 2008; 173: 253-264.
143. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182: 1746-1755.
144. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725. (Pubitemid 26282179)
145. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-4732.
146. Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, Sagawa K, et al. Novel low molecular weight spirodiketo-piperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 2001; 276: 35194-35200. (Pubitemid 37384528)
147. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 12718-12723. (Pubitemid 33020012)
148. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999; 96: 5698-5703. (Pubitemid 29234681)
149. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44: 591-595. (Pubitemid 46233265)
150. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-698.
151. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 2003; 105: 186-189. (Pubitemid 36505319)
152. Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 2002; 62: 2937-2941. (Pubitemid 34525782)
153. Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y, et al. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol 2007; 18: 70-76. (Pubitemid 46152502)
154. Hedrick JA, Zlotnik A. Identification and characterization of a novel beta chemokine containing six conserved cysteines. J Immunol 1997; 159: 1589-1593. (Pubitemid 127484140)
155. Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999; 189: 451-460. (Pubitemid 29187367)
156. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 2005; 11: 5686-5693. (Pubitemid 41170291)
157. Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DS. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004; 10: 2351-2358. (Pubitemid 38445693)
158. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001; 93: 1638-1643. (Pubitemid 33094871)
159. Gunther K, Leier J, Henning G, Dimmler A, Weissbach R, Hohenberger W, et al. Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. Int J Cancer 2005; 116: 726-733. (Pubitemid 41099704)
160. Wang J, Xi L, Gooding W, Godfrey TE, Ferris RL. Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol 2005; 62: 121-133. (Pubitemid 40014311)
161. Heresi GA, Wang J, Taichman R, Chirinos JA, Regalado JJ, Lichtstein DM, et al. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol 2005; 23: 261-267. (Pubitemid 40961938)
162. Ding Y, Shimada Y, Maeda M, Kawabe A, Kaganoi J, Komoto I, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 2003; 9: 3406-3412. (Pubitemid 37082736)
163. Yan C, Zhu ZG, Yu YY, Ji J, Zhang Y, Ji YB, et al. Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol 2004; 10: 783-790. (Pubitemid 38418346)
164. Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007; 11: 526-538. (Pubitemid 46856909)
165. fonso-Perez M, Lopez-Giral S, Quintana NE, Loscertales J, Martin-Jimenez P, Munoz C. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol 2006; 79: 1157-1165.
166. Bajetto A, Barbieri F, Dorcaratto A, Barbero S, Daga A, Porcile C, et al. Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation and migration. Neurochem Int 2006; 49: 423-432. (Pubitemid 44189638)
167. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 2005; 11: 4117-4127. (Pubitemid 40791576)
168. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005; 175: 5351-5357. (Pubitemid 41456421)
169. Richards BL, Eisma RJ, Spiro JD, Lindquist RL, Kreutzer DL. Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma. Am J Surg 1997; 174: 507-512. (Pubitemid 27486015)
170. Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994; 179: 1409-1415.
171. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996; 97: 2792-2802. (Pubitemid 26197092)
172. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998; 102: 465-472. (Pubitemid 28376148)
173. Zhu YM, Bagstaff SM, Woll PJ. Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1beta and hypoxia in small cell lung cancer. Br J Cancer 2006; 94: 1936-1941.
174. Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 2000; 162: 1957-1963. (Pubitemid 30947587)
175. Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A, et al. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 2001; 92: 2628-2638. (Pubitemid 33049447)
176. Orditura M, De VF, Catalano G, Infusino S, Lieto E, Martinelli E, et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 2002; 22: 1129-1135. (Pubitemid 36051185)
177. White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003; 9: 853-860. (Pubitemid 36182624)
178. Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003; 9: 729-737. (Pubitemid 36182607)
179. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998; 90: 447-454. (Pubitemid 28160636)
180. Fregene TA, Khanuja PS, Noto AC, Gehani SK, Van Egmont EM, Luz DA, et al. Tumor-associated angiogenesis in prostate cancer. Anticancer Res 1993; 13: 2377-2381.
181. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000; 6: 2104-2119. (Pubitemid 30305111)
182. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 2000; 60: 2290-2299. (Pubitemid 30225196)
183. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 1997; 28: 321-331. (Pubitemid 27106085)
184. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54: 3242-3247. (Pubitemid 24208936)
185. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-583. (Pubitemid 32112873)
186. Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006; 125: 209-216.
187. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002; 161: 125-134. (Pubitemid 34760778)
188. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999; 5: 3711-3721.
189. Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, et al. Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 2003; 9: 2786-2797. (Pubitemid 36842125)
190. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 2003; 9: 3167-3175. (Pubitemid 36993279)
191. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005; 65: 11001-11009. (Pubitemid 41713370)
192. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-1313.
193. Collins TS, Lee LF, Ting JP. Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol Immunother 2000; 49: 78-84.
194. De Larco JE, Wuertz BR, Manivel JC, Furcht LT. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 2001; 61: 2857-2861.
195. Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004; 22: 2092-2100. (Pubitemid 41095142)
196. Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factorkappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 2008; 327: 746-759.
197. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008; 100: 359-372.
198. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
199. Winters MP, Crysler C, Subasinghe N, Ryan D, Leong L, Zhao S, et al. Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor. Bioorg Med Chem Lett 2008; 18: 1926-1930.
200. Lai G, Merritt JR, He Z, Feng D, Chao J, Czarniecki MF, et al. Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists. Bioorg Med Chem Lett 2008; 18: 1864-1868.
201. Walters I, Austin C, Austin R, Bonnert R, Cage P, Christie M, et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett 2008; 18: 798-803.
202. Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 2007; 322: 477-485.
203. McCleland BW, Davis RS, Palovich MR, Widdowson KL, Werner ML, Burman M, et al. Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett 2007; 17: 1713-1717. (Pubitemid 46274338)
204. Dwyer MP, Yu Y, Chao J, Aki C, Chao J, Biju P, et al. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2- yl)propyl]amino]-3,4- dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J Med Chem 2006; 49: 7603-7606. (Pubitemid 46033652)
205. Zhu YM, Webster SJ, Flower D, Woll PJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 2004; 91: 1970-1976. (Pubitemid 40065527)
206. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999; 154: 1503-1512. (Pubitemid 29226445)
207. Kleinhans M, Tun-Kyi A, Gilliet M, Kadin ME, Dummer R, Burg G, et al. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood 2003; 101: 1487-1493. (Pubitemid 36182525)
208. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci 2005; 96: 317-322.
209. Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007; 110: 3316-3325.
210. Andreasson U, Ek S, Merz H, Rosenquist R, Andersen N, Jerkeman M, et al. B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett 2008; 259: 138-145. (Pubitemid 350251646)
211. Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer 2008; 99: 930-938.
212. Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res 2008; 68: 4701-4708.
213. Milliken D, Scotton C, Raju S, Balkwill F, Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002; 8: 1108-1114. (Pubitemid 35177363)
214. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009; 69: 1685-1692.
215. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004; 64: 4693-4698. (Pubitemid 38924507)
216. Ghadjar P, Loddenkemper C, Coupland SE, Stroux A, Noutsias M, Thiel E, et al. Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol 2008; 134: 1181-1189.
217. Gutwein P, Schramme A, Sinke N, bdel-Bakky MS, Voss B, Obermuller N, et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 2009; 45: 478-489.
218. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002; 102: 220-224. (Pubitemid 35222287)
219. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003; 63: 7451-7461. (Pubitemid 37413488)
220. Cheadle EJ, Riyad K, Subar D, Rothwell DG, Ashton G, Batha H, et al. Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res 2007; 13: 5719-5728. (Pubitemid 47583896)
221. Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A, et al. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 2006; 24: 1910-1916. (Pubitemid 46646227)
222. Huang J, Hu J, Bian X, Chen K, Gong W, Dunlop NM, et al. Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells. Cancer Res 2007; 67: 5906-5913. (Pubitemid 46985026)
223. Huang J, Chen K, Gong W, Zhou Y, Le Y, Bian X, et al. Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression. Cancer Lett 2008; 267: 254-261.
224. Rabiet MJ, Huet E, Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol 2005; 35: 2486-2495. (Pubitemid 41179770)
225. Xia SH, Hu LP, Hu H, Ying WT, Xu X, Cai Y, et al. Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas. Oncogene 2002; 21: 6641-6648. (Pubitemid 35177043)
226. Sun R, Iribarren P, Zhang N, Zhou Y, Gong W, Cho EH, et al. Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J Immunol 2004; 173: 428-436. (Pubitemid 38797369)
227. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol 2002; 23: 541-548.
228. Rescher U, Danielczyk A, Markoff A, Gerke V. Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells. J Immunol 2002; 169: 1500-1504. (Pubitemid 34809196)
229. McCoy R, Haviland DL, Molmenti EP, Ziambaras T, Wetsel RA, Perlmutter DH. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J Exp Med 1995; 182: 207-217.
230. Zhou Y, Bian X, Le Y, Gong W, Hu J, Zhang X, et al. Formyl-peptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst 2005; 97: 823-835. (Pubitemid 40909125)
231. Bifulco C, McDaniel K, Leng L, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des 2008; 14(36): 3790-3801
232. Cutler C, Antin JH. Novel drugs for the prevention and treatment of acute GVHD. Curr Pharm Des 2008; 14(20): 1962-1973
233. Robertson JH, Iga AM, Sales KM, Winslet MC, Seifalian AM. Integrins: a method of early intervention in the treatment of colorectal liver metastases. Curr Pharm Des 2008; 14(3): 296-305.